Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 205Breast Neoplasms 187Neoplasms 167Leukemia, Myeloid, Acute 164Multiple Myeloma 157Lymphoma 120Melanoma 117Neoplasm Metastasis 114Lymphoma, Non-Hodgkin 110Prostatic Neoplasms 109Leukemia 107Colorectal Neoplasms 96Recurrence 91Leukemia, Lymphocytic, Chronic, B-Cell 90Pancreatic Neoplasms 85Ovarian Neoplasms 85Myelodysplastic Syndromes 83Lung Neoplasms 83Lymphoma, Follicular 78Glioblastoma 78Precursor Cell Lymphoblastic Leukemia-Lymphoma 77Lymphoma, Large B-Cell, Diffuse 77Hodgkin Disease 69Lymphoma, Mantle-Cell 65Carcinoma, Renal Cell 62Brain Neoplasms 56Small Cell Lung Carcinoma 55Squamous Cell Carcinoma of Head and Neck 54Triple Negative Breast Neoplasms 52Sarcoma 52

Interventions

HhAntag691 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Malignant mesenchymal tumor × Clear all
NCT01154452 2018-08-15

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
78 enrolled 11 charts
GastrointestinalSarcoma

Malignant mesenchymal tumor, Chondrosarcoma, Extraskeletal Myxoid, Chondrosarcoma, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Sarcoma, Alveolar Soft Part, Neuroectodermal Tumors, Primitive, Peripheral, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Gastrointestinal Stromal Tumors, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡